New treatment approved in Canada for most common type of leukaemia

AstraZeneca

8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia.

AstraZeneca Canada today announced that Health Canada has approved Calquence (acalabrutinib), an oral Bruton's tyrosine kinase inhibitor, for the treatment of adult patients with chronic lymphocytic leukaemia, as monotherapy or in combination with obinutuzumab in the first-line setting, and as monotherapy for relapsed/refractory disease.

The Canadian approval was granted under Project Orbis, a new international health authority collaboration which provides a framework for simultaneous submission and review of oncology products among international partners.5 Under this collaboration, Health Canada, the U.S. FDA, and the Australian Therapeutic Goods Administration collectively reviewed the application for Calquence, making it the second treatment approved as part of the program and the first in haematology.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada